Sildenafil Tablet, Film Coated
Product Images NDC 70518-1844

11 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 70518-1844). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafilchemicalstructure (Sildenafilchemicalstructure)

Sildenafilchemicalstructure (Sildenafilchemicalstructure)
Chemical structure of Sildenafil, showing its molecular components including sulfonamide, pyrazolo-pyrimidine core, and carboxylic acid groups.*
FDA Label Image

Sildenafilfig1 (Sildenafilfig1)

Sildenafilfig1 (Sildenafilfig1)
A line graph showing the change in systolic blood pressure (SBP) over time (hours) post-dose. It compares two groups: Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg. The y-axis measures change in SBP in mmHg, and the x-axis shows time up to 8 hours post-dose, illustrating blood pressure trends for each treatment combination.*
FDA Label Image

Sildenafilfig2 (Sildenafilfig2)

Sildenafilfig2 (Sildenafilfig2)
A line graph showing changes in systolic blood pressure (SBP) over an 8-hour period post dose. The graph compares two groups: one receiving Doxazosin with Placebo and the other Doxazosin with Sildenafil 25 mg. The y-axis measures change in SBP (mmHg) ranging from -40 to 20, and the x-axis shows time post dose in hours from 0 to 8.*
FDA Label Image

Sildenafilfig3 (Sildenafilfig3)

Sildenafilfig3 (Sildenafilfig3)
A line chart showing the change in systolic blood pressure (SBP) over time post dose (hours). It compares two treatments: Doxazosin with Placebo and Doxazosin with Sildenafil 50 mg. The y-axis measures change in SBP in mmHg, ranging from -50 to 40, and the x-axis measures time from 0 to 8 hours post dose. The chart displays trends indicating different SBP changes for each treatment over the time period.*
FDA Label Image

Sildenafilfig4 (Sildenafilfig4)

Sildenafilfig4 (Sildenafilfig4)
A line graph showing blood pressure changes (mmHg) over time (hours) after dosing with Doxazosin combined with Sildenafil 100 mg and Doxazosin combined with placebo. The graph tracks measurements from 0 to 8 hours, with two lines representing each treatment group and indicating trends in blood pressure reduction post-dose.*
FDA Label Image

Sildenafilfig5 (Sildenafilfig5)

Sildenafilfig5 (Sildenafilfig5)
A line graph depicting plasma concentration (ng/mL) of Sildenafil over time post dose (hours) for a commercial tablet. The graph shows concentration peaking shortly after dosing around 1 hour and gradually declining to near zero by 24 hours.*
FDA Label Image

Sildenafilfog6a (Sildenafilfog6a)

Sildenafilfog6a (Sildenafilfog6a)
A bar chart depicting the percentage of patients at endpoint on the vertical axis, with six grouped bars for values 0 through 5 on the horizontal axis. Each group contains bars representing different categories labeled as 0, 1, 2, 3, 4, and 5. The chart likely compares patient outcomes or responses in several categories across the groups.*
FDA Label Image

Sildenafilfog6b (Sildenafilfog6b)

Sildenafilfog6b (Sildenafilfog6b)
A bar chart displaying the percentage of patients at endpoint across different categories labeled 0 to 5 on the x-axis. The y-axis shows the percentage of patients, ranging from 0 to 80%. Multiple bars within each category represent various subgroups indicated by a numbered legend (0 to 5), showing different patient percentages per group.*
FDA Label Image

Sildenafilfig7 (Sildenafilfig7)

Sildenafilfig7 (Sildenafilfig7)
A bar graph showing the percentage of patients reporting improvement across different treatment groups: Placebo (24%, n=463), Sildenafil Tablets 25 mg (63%, n=214), Sildenafil Tablets 50 mg (74%, n=391), and Sildenafil Tablets 100 mg (82%, n=380). The overall treatment significance is noted as p<0.0001.*
FDA Label Image

Mm1 (Sildenafil 50mg 70518 1844 00)

Mm1 (Sildenafil 50mg 70518 1844 00)
Sildenafil 50 mg oral film-coated tablets label by RemedyRepack Inc. The label states the quantity as 30 tablets and notes the product is prescription-only (RX ONLY). It includes the NDC number 70518-1844-00, manufacturer details (Camber Pharma, Inc., Piscataway, NJ), and storage directions with a QR code visible on the right side.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Sildenafil 50 mg film-coated tablets, quantity of 30 tablets per bottle. The label indicates the product is repackaged by RemedyRepack Inc., based in Indiana, PA, with storage instructions and a manufacturer listed as Camber Pharma, Inc. The NDC number is 70518-1844-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.